Why Chick-Fil-A Operations Saved a COVID Vaccine Drive-Thru

 

Fast-food giant Chick-Fil-A is known for its service – and that commitment to moving customers through its restaurants paid off outside the realm of chicken sandwiches recently.

A South Carolina Chick-Fil-A came through in a big way for the local community of Mount Pleasant, highlighting some of the ways Chick-Fila-A has commanded the drive-thru and its excellent customer experience.

Reporting out of FOX 11 said that, on Jan. 22nd, traffic at a local COVID-19 vaccination site was so backed up, patients getting a vaccine were waiting for an hour or more. The issue was initially caused by a software glitch, which delayed vaccine administering for too long a period to recover from – at least without help.

When the Mayor of Mount Pleasant, Will Haynie, was notified, his first thought to solve the issue was to ring the manager of one of the town’s Chick-Fil-A locations.

It proved a savvy move, as manager Jerry Walkowiak brought some of the restaurant’s best practices to the drive-thru to speed things along, such as going down the car line as people waited to make sure they had paperwork all filled out and ready to go and getting them to a parking spot to receive their vaccine.

It raises an important point – how has Chick-Fil-A built such a reputation for excellent customer service when, in fact, their drive-thrus came in dead last for speed compared to nine other major chains in a recent study?

On this MarketScale Industry Update, hosts Daniel Litwin and Tyler Kern dive into how good service, accuracy and more can make up for a lack of speed – and how the word “frictionless” doesn’t have to mean “lightspeed.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More